Breast Cancer

A review of the potential agents or regimens that Allison Butts, PharmD, BCOP, is looking forward to seeing transition from metastatic management to the early stage setting.

In the United States, these findings would translate to more than 269,000 prevented breast cancer cases and nearly 44,000 prevented cases of ovarian cancer.
 

Experts in the field of breast cancer management review the data from the ExteNET and TRAIN-2 Trials.

Pharmacists in the breast cancer field discuss the role for disease-free survival as an end point and the implications of the KATHERINE trial.

Both premenopausal and postmenopausal breast cancer rates are rising globally. 

Following initial breast cancer diagnosis by mammography, MRI, or ultrasound, treatment is largely based upon the histologic subtype and staging of the tumor(s).

Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, share insights on some recent trials for early stage breast cancer, specifically the APHINITY trial.

Earlier results of the FAST trial, which was launched in 2004, found that reducing the number of radiotherapy fractions to 5 was feasible and safe in the short term.

The selection of an agent for hyperglycemia management requires knowledge of both the efficacy and the potential adverse effects of each possible agent, so choosing the best therapy for any given patient can be complicated.

In addition to its potential uses in cancer treatment, this novel drug delivery system could be used with magnetic resonance imaging or fluorescence imaging.

The presence of ctDNA and CTCs in the plasma of the blood of women who have undergone chemotherapy prior to surgery for the treatment of triple-negative breast cancer (TNBC) are critical indicators in the prediction of disease recurrence and disease-free survival.

Since 2015, there has been an increase in the number of specialty pharmacies in the United States due to their potential of handling the complexities of cost and appropriate drug access and administration.